|
|
- 2018
Description of Baseline Characteristics of Pediatric Allergic Asthma Patients Including those Initiated on OmalizumabKeywords: allergic asthma, moderate-to-severe asthma, uncontrolled asthma, omalizumab, anti-immunoglobulin E antibody, biologic, pediatric asthma, electronic medical records, baseline characteristics, clinical profile Abstract: Indication of omalizumab in the United States was recently extended to include pediatric (6–11 years) uncontrolled moderate-to-severe allergic asthma patients
|
